RxDoctor Payments Data

Erik Istre, MD

Neurology · Queensbury, NYNPI 1912228669

Payments from drug & device makers

$22,385in general payments, 2019–2025

Across 367 payments — averaging $61.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$17K
  • EMD Serono, Inc.$1K
  • Sanofi$689
  • Genentech USA, Inc.$517
  • Axsome Therapeutics, Inc.$431
  • Biogen$389
  • plus $2K from 27 others

What the payments were for

  • Speaking & faculty fees$12,33855%
  • Food & beverage$10,00445%
  • Education$430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,385 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$143,506
Medicare patients
199
Services billed
14,689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate200$286,206
TecfideraDimethyl Fumarate15$205,846
BriviactBrivaracetam83$182,275
AmpyraDalfampridine33$164,913
Nurtec OdtRimegepant Sulfate105$142,372
GilenyaFingolimod Hcl19$127,185
UbrelvyUbrogepant97$125,171
Kesimpta PenOfatumumab14$117,845
MayzentSiponimod11$99,652
AptiomEslicarbazepine Acetate79$86,400
CopaxoneGlatiramer Acetate14$85,692
Dalfampridine ErDalfampridine102$76,524
NuplazidPimavanserin Tartrate12$63,220
QuliptaAtogepant41$56,480
NuedextaDextromethorphan Hbr/Quinidine31$52,622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$353$286,206200 claims
NovartisGilenya, Mayzent$304$226,83730 claims
BiogenTecfidera$389$205,84615 claims
UCB, Inc.Briviact, Vimpat$26$197,27395 claims
AbbVieUbrelvy, Qulipta$16,879$181,651138 claims
PfizerNurtec Odt$116$142,372105 claims
Sunovion Pharmaceuticals Inc.Aptiom$18$86,40079 claims
Teva Pharmaceuticals USA, Inc.Copaxone$15$85,69214 claims
Avanir Pharmaceuticals, Inc.Nuedexta$15$52,62231 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$20$34,37812 claims
Axsome Therapeutics, Inc.Auvelity$431$34,34931 claims
Eisai Inc.Fycompa$21$16,88213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.

Other neurology in Queensbury

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →